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In the previous issue of Critical Care, Mondello and 
colleagues [1] demonstrate that easy to obtain bio  chemi  cal 
markers of brain injury in peripheral blood may comple-
ment current predictors of outcome in severe traumatic 
brain injury (TBI). Th  e study also advocates that use of 
biomarkers may contribute to better understanding of 
the pathophysiological mechanisms of brain damage. 
After TBI, brain tissue-speciﬁ   c neuronal and glial 
proteins may suddenly appear in the systemic circulation 
via leakage through the disturbed blood brain barrier or 
via leakage to the cerebrospinal ﬂ   uid and subsequent 
normal transport to the circulation. Despite the strength 
of the association between existing predictors of out  come, 
the prognostic value is still modest. Studies in more than 
10,000 patients demonstrate a diagnostic accuracy of 0.70 
to 0.84, which is insuﬃ   cient as a diagnostic and prog-
nostic tool in individual patients [2,3]. Current models 
explain only 35% of the outcome variation [4]. Consider-
ing the large proportion of outcome variation that 
remains unexplained, the models need to be reﬁ  ned [5].
Mondello and colleagues determined in a cohort of 81 
severe TBI patients the time course of neuronal (ubiqui-
tin carboxy-terminal hydrolase (UCH)-L1) and astroglial 
(glial ﬁ  brillary acidic protein (GFAP)) biomarker levels in 
serum in the ﬁ  rst 24 hours after severe focal and diﬀ  use 
injuries. UCH-L1 and GFAP were selected because of 
abundant expression in neurons (UCH-L1) and 
astrocytes (GFAP). UCH-L1 is involved in the addition or 
removal of ubiquitin from abnormal proteins destined for 
protea  somal degradation and has previously been used as 
a neuronal cell soma marker [6]. Initial results in cerebro-
spinal ﬂ  uid showed higher levels of UCH-L1 in patients 
with low Glasgow Coma Scale (GCS) scores, post-injury 
complica  tions, early mortality and poor 6-month 
outcome. GFAP was chosen because of its high speciﬁ  city 
for central nervous system astrocytes and its strong 
association with GCS, injury severity, intra  cranial 
pathology and outcome after TBI [7,8].
Interestingly, the study shows markedly increased serum 
levels for UCH-L1 (11.3-fold) and GFAP (28.7-fold) in 
the ﬁ  rst 24 hours post-injury compared to controls. Using 
the intracranial diagnosis of the Trauma Coma Data Bank 
classiﬁ  cation, diﬀ  erent pathways for UCH-L1 and GFAP 
were found; UCH-L1 levels were high in diﬀ  use injuries 
and GFAP serum levels were particularly increased in the 
presence of focal mass lesions. In the prediction of 
outcome, the combination of UCH-L1, age and GCS 
score predicted death at 6 months post-injury with an 
accuracy of 94%, although the combination of GFAP and 
age was equally predictive. Th  is corroborates recent 
ﬁ  ndings demonstrating that GFAP serum levels highly 
correlate with the presence of focal lesions on computed 
tomography (r  =  0.73) [7]. Multivariate modeling to 
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Traumatic brain injury (TBI) is a pathologically 
heterogeneous disease aff  ecting people of all ages. 
The highest incidence of TBI occurs in young people 
and the average age is 30 to 40 years. Injury grading 
may range from mild with a low frequency (1 per 
100) of life-threatening intracranial hematoma that 
needs immediate neurosurgical operation and very 
low mortality (1 per 1,000) to severe with a high 
likelihood of life-threatening intracranial hematoma 
(up to 1 per 3), a 40% case fatality rate and a high 
disability rate (2 per 3) in survivors. Estimation of 
the prognosis in severe TBI is currently based on 
demographic and clinical predictors, including age, 
Glasgow Coma Scale, pupillary reactions, extracranial 
injury (hypotension and hypoxia) and computed 
tomography indices (brain swelling, focal mass lesions, 
subarachnoid hemorrhage). Biomarkers refl  ecting 
damage to neurons and astrocytes may add important 
complementary information to clinical predictors of 
outcome and provide insight into the pathophysiology 
of TBI.
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the combination of GFAP with pupillary reactions and 
0.92 for the combination of GFAP with mass lesions.
Th   e study by Mondello and colleagues focused on focal 
versus diﬀ  use injuries deﬁ  ned by computed tomography 
rather than magnetic resonance imaging. Th  is  dichotomi-
zation did not allow the levels of biomarkers in patients 
with mixed focal and diﬀ  use pathology to be studied. 
Recent magnetic resonance imaging demonstrates that 
focal and diﬀ  use injuries occur separately but also coexist 
in moderate/severe TBI. Pure forms of focal injury occur 
in 28% of moderate/severe TBI cases, pure diﬀ  use axonal 
injury in 22%, while mixed focal and diﬀ  use  injuries 
occur in 50% [9]. Th   e cohort size of 81 in this transatlantic 
study in four centers limits the number of potential 
predictors that could be assessed and only three (age, 
UCH-L1, GCS) were included in the ﬁ   nal model to 
predict mortality.
Th   e investigation did not obtain other outcome 
measures (global or cognitive) than mortality (in hospital 
and at 6 months). Knowing that a biomarker predicts 
mortality, however, is important when treatment limita-
tion or withdrawal is considered. In this study UCH-L1 
together with age and the GCS were included in the ﬁ  nal 
model, suggesting that biomarker test results are speciﬁ  c 
for a particular outcome category (death) and may 
increase the conﬁ  dence with which ﬁ  nal decisions can be 
made.
More importantly, however, will biomarkers ultimately 
add to the prediction of long-term outcome of survivors 
to answer whether a patient will reach independency 
from care givers or return to work? In this respect it is 
promising that diﬀ  erent results were obtained for the two 
markers with diﬀ  use and focal injuries. Th  e  importance 
of the pathological heterogeneity of focal and diﬀ  use TBI 
lies in the fact that patients with the same GCS score can 
have markedly diﬀ   erent treatments, recovery patterns 
and outcomes depending on the causative lesion.
A challenging next step is to obtain cutoﬀ   levels for 
neuronal and glial markers of TBI with small false-
positive rates not only for death but also for global 
unfavorable outcome measures such as disability or 
cognitive dysfunction. To achieve this goal, larger 
(multicenter) studies are needed to establish precise 
threshold values and to demonstrate that information 
obtained from biomarkers in addition to clinical variables 
indeed allows for suﬃ   ciently accurate outcome predic-
tion in individual patients. In addition, it will be interest-
ing if prolonged determination of biomarker levels in the 
acute phase can be associated with secondary complica-
tions such as increased intracranial pressure, decreased 
cerebral perfusion pressure and eﬀ  ects of treatment.
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